在特朗普總統(tǒng)于沃爾特?里德醫(yī)院住院期間接受的各種試驗性新冠治療藥物和補充劑中,最受關注的是Regeneron公司開發(fā)的一種單克隆抗體混合藥物。
該公司已公布的初步數(shù)據(jù)表明,這種通過結合實驗室制造的抗體來治療多種疾病的方法,已證明其成功阻止了無癥狀患者患者病情繼續(xù)加重乃至住院治療。
周三,另一家制藥巨頭Eli Lilly公司表示,他們在使用這種方法時也得到了類似的結果,并有足夠的信心尋求食品和藥物管理局(FDA)緊急使用授權(EUA)。
與Regeneron公司的聲明和迄今為止的臨床試驗數(shù)據(jù)相類似,Eli Lilly公司的抗體混合藥物能在病人接受治療的11天內顯著降低其體內的病毒載量(病毒活躍的數(shù)量),從而大幅削減醫(yī)院急診室的使用數(shù)量。該實驗療法被稱為LY-CoV555和LY-CoV016,它們可以防止冠狀病毒附著、感染細胞。
Lilly公司的數(shù)據(jù)看起來似乎是好消息。讓人們遠離醫(yī)院、急診室,正是我們的現(xiàn)實需求。
——Brad Loncar (@bradloncar),2020年10月7日
隨著連續(xù)兩種藥物顯示抗體混合藥物療法可能有效,其他公司或將研究同樣的方法。
但是,這些療法僅對輕度到中度的新冠患者顯示出療效(重要的是,沒有嚴重的副作用)。已經住院的重病患者可能是另一回事。
藥物的可獲得性將是一個需要解決的關鍵細節(jié),因為大規(guī)模生產抗體藥物比制造簡單的化學療法要復雜得多。
Lilly公司此前曾表示,該公司的一種抗體療法將在10月份生產10萬劑——因為該公司在研發(fā)這種藥物時就已經考慮過量產。該公司在一份電子郵件新聞稿中表示,今年晚些時候,還有數(shù)萬劑的聯(lián)合療法可能面世。(財富中文網)
編譯:楊二一
在特朗普總統(tǒng)于沃爾特?里德醫(yī)院住院期間接受的各種試驗性新冠治療藥物和補充劑中,最受關注的是Regeneron公司開發(fā)的一種單克隆抗體混合藥物。
該公司已公布的初步數(shù)據(jù)表明,這種通過結合實驗室制造的抗體來治療多種疾病的方法,已證明其成功阻止了無癥狀患者患者病情繼續(xù)加重乃至住院治療。
周三,另一家制藥巨頭Eli Lilly公司表示,他們在使用這種方法時也得到了類似的結果,并有足夠的信心尋求食品和藥物管理局(FDA)緊急使用授權(EUA)。
與Regeneron公司的聲明和迄今為止的臨床試驗數(shù)據(jù)相類似,Eli Lilly公司的抗體混合藥物能在病人接受治療的11天內顯著降低其體內的病毒載量(病毒活躍的數(shù)量),從而大幅削減醫(yī)院急診室的使用數(shù)量。該實驗療法被稱為LY-CoV555和LY-CoV016,它們可以防止冠狀病毒附著、感染細胞。
Lilly公司的數(shù)據(jù)看起來似乎是好消息。讓人們遠離醫(yī)院、急診室,正是我們的現(xiàn)實需求。
——Brad Loncar (@bradloncar),2020年10月7日
隨著連續(xù)兩種藥物顯示抗體混合藥物療法可能有效,其他公司或將研究同樣的方法。
但是,這些療法僅對輕度到中度的新冠患者顯示出療效(重要的是,沒有嚴重的副作用)。已經住院的重病患者可能是另一回事。
藥物的可獲得性將是一個需要解決的關鍵細節(jié),因為大規(guī)模生產抗體藥物比制造簡單的化學療法要復雜得多。
Lilly公司此前曾表示,該公司的一種抗體療法將在10月份生產10萬劑——因為該公司在研發(fā)這種藥物時就已經考慮過量產。該公司在一份電子郵件新聞稿中表示,今年晚些時候,還有數(shù)萬劑的聯(lián)合療法可能面世。(財富中文網)
編譯:楊二一
Among the various experimental COVID-19 drugs and supplements that President Trump received during his stay at Walter Reed hospital, one of the most closely-watched is a cocktail of monoclonal antibodies being developed by Regeneron.
The company had released preliminary data suggesting that this approach, which combines lab-created antibodies in order to treat a variety of diseases, suggesting that it was successful in preventing serious hospitalization in patients who weren't too far along in showing coronavirus symptoms.
On Wednesday, another company, the drug giant Eli Lilly, said that it had seen similar results using this method and is confident enough to seek Food and Drug Administration (FDA) emergency use authorization (EUA).
Similar to Regeneron's claims and the clinical trial data it's unveiled to date, Eli Lilly's antibody cocktail was able to significantly reduce viral load (the amount of virus active) in patients who received the treatment within 11 days and significantly slashed the need for emergency room use or hospitalization. The experimental therapies are called LY-CoV555 and LY-CoV016, and they prevent the coronavirus from actually latching on to and infecting cells.
Lilly data looks like terrific news. Keeping people out of the hospital and ER is the real world benefit we are looking for. pic.twitter.com/n0BnQGUcLY
— Brad Loncar (@bradloncar) October 7, 2020
With two consecutive drugs showing that the antibody cocktail method could be significantly effective, other companies may dig into that same approach.
However, these treatments are showing efficacy (and, importantly, a lack of serious side effects) in those with mild-to-moderate COVID cases. The seriously ill who are already hospitalized could be a different story.
Availability is a key detail that needs to be worked out since mass production of an antibody drug is far more complicated than creating simpler chemical treatments.
Lilly has previously said that it will be able to produce 100,000 doses of one of its antibody therapies in October since it had already considered manufacturing while creating the drug. Tens of thousands more doses of the combination therapy could be available later this year, the company said in an emailed press release.